1. Medicines Transparency Alliance27/10/2015 1 MeTA Ghana Augustina Koduah (Mrs) Country Coordinator

2. Medicines Transparency Alliance27/10/20152 Multi-stakeholder process [What were the major milestone in the multi-stakeholder process?] Inaugural Meeting of Governing Council by Deputy Minister in September 2008 Official Launch in November 2008 First National forum in December 2009 CSO & Media Orientation in April 2009 Quarterly Governing Council Meetings to date Independent monitoring of medicines quality through routine testing with FDB & monitoring access to medicines using NHIS data based on agreed indicators with NHIA established Participated in major MeTA led International activities [MIAG & Jordan Training] Launch and Sensitization of Ghana MeTA CSO Group community targeted communication activities in April 2010

3. Medicines Transparency Alliance27/10/20153 Picture & Text example Multi-stakeholder analysis workshop carried out in June 2010 National Multi- stakeholder Technical discussion forum on data disclosure in June 2010

4. Medicines Transparency Alliance Major achievements and successes [What where the main achievements and successes of MeTA in your country? ] Active Multi-stakeholder Council made up of excellent spread of relevant stakeholders with sub committees (Administration, Advocacy & Technical) & a strong interest to move forward towards regular dialogue on medicines issues Independent Secretariat & Functional Website www.metaghana.orgwww.metaghana.org Facilitated an active independent civil society capacity to lead consumer advocacy campaign to support disclosure and accountability on access to medicines Baseline Pharmaceutical disclosure survey & sector scan studies completed Good collaboration established with NHIA to use data to monitor access to medicines based on agreed indicators with promising public health benefits Case studies shared with other MeTA countries through international meetings and country exchange visits 27/10/20154

5. Medicines Transparency Alliance27/10/20155 Major Achievement Results of Routine Minilab Quality Assurance Test led to necessary regulatory interventions

6. Medicines Transparency Alliance Overall challenges [What have been the main challenges during the MeTA pilot phase? ] Initial unclear Standard Operating Procedures Latent mutual suspicion between the state and private sector; Nervousness of some stakeholders about change; MeTA assumes that enforcement mechanisms exist across the medicines manufacture, import, procurement and distribution systems, but historically enforcement of regulations is weak; Slow and Bureaucratic Decision Making process Maintaining momentum of stakeholders over time. (Diminishing returns) Working together to build trust & understanding between different stakeholders is difficult Timeliness and sustainability of financing beyond the pilot phase. 27/10/20156

7. Medicines Transparency Alliance Lessons Learned [What are the main lessons from MeTA in your country? ] Players in the pharmaceutical sector have varying interest and power Multi-stakeholder groups in the pharmaceutical sector have a better understanding of each other through transparent and systematic engagement Potential to make a positive impact in medicines access through transparent multi-stakeholder and systematic data sharing and disclosure works. Providing Ghanaian leadership on medicines transparency disclosure and dissemination of information to eliminate the risk of counterfeit and substandard medication as well as pricing in the supply chain 27/10/20157

8. Medicines Transparency Alliance27/10/20158 Thank you Name of presenter : Augustina Koduah (Mrs) Email: appidanq@yahoo.com Mobile number: +233 20 8769228 Skype: Website: